The World Health Organization has prequalified the Typbar-TCV typhoid conjugate vaccine, offering longer-lasting protection and allowing administration to children under two years old. This step is crucial in expanding access to this lifesaving vaccine and reducing the burden of typhoid in high-risk areas.
Neglected tropical diseases (NTDs) threaten Indonesia's economic growth and development, particularly for women and children. The country has an opportunity to scale up national programs and integrate NTDs with other development efforts.
A new consortium led by the Sabin Vaccine Institute is conducting clinical trials of a human hookworm vaccine in Gabon. The vaccine has the potential to dramatically improve health, economic, and social landscapes in countries with high burdens of hookworm disease.
The Sabin Vaccine Institute has launched the International Association of Immunization Managers (IAIM) to help drive national, regional, and international immunization goals. IAIM aims to equip immunization managers with tools and a professional network to advance their programs.
A new study suggests that pneumococcal disease may be shifting its burden from infants to adults in Latin America, with significant economic implications. The research highlights the need for increased monitoring and surveillance to understand the full extent of the disease in the region.
Chagas disease infects an estimated 10 million people worldwide, causing significant economic burden, including USD $6.7 billion in future healthcare costs in the United States.
The study highlights links between NTDs and socio-economic prosperity, finding that integrated treatment efforts are cost-effective public health interventions. The report recommends prioritizing NTD programs worldwide to improve health and prosperity for over 1 billion people.
Sanofi Pasteur's CYD-TDV vaccine candidate has shown promise in a phase IIb clinical trial, with effectiveness against DENV 1, 3 and 4 but not DENV 2. The results mark a significant step forward in dengue vaccine development.
A new study published in Vaccine indicates that the cost of producing a tetravalent dengue vaccine could be as low as $0.20 per dose with an annual production level of 60 million doses. This finding provides confidence to ministries of health to plan for the inclusion of dengue vaccine in their immunization programs.
Despite progress in vaccine distribution for childhood killer diseases, global efforts to combat neglected tropical diseases (NTDs) are lagging, argue researchers. NTDs, which affect the world's poorest, require more R&D funding and investment to develop effective vaccines.
The Dengue Vaccine Initiative aims to accelerate the development and utilization of safe, affordable, and broadly protective vaccines to combat dengue fever. The initiative will generate data on the burden of disease, potential private demand, cost of illness, and seroprevalence in several countries.